Matrix-Producing Cells in Chronic Kidney Disease: Origin, Regulation, and Activation

Current Pathobiology Reports

Volumn 1, Issue 4, 2013, Pages 301-311

  Kramann, Rafael ^a,b,c   DiRocco, Derek P ^a,b   Maarouf, Omar H ^a,b   Humphreys, Benjamin D ^a,b,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Capillary rarefaction; Chronic kidney disease; Interstitium; Matrix producing cells; Myofibroblast; Pericyte

Indexed keywords

EID: 84907044310     PISSN: None     EISSN: 2167485X     Source Type: Journal    
DOI: 10.1007/s40139-013-0026-7     Document Type: Review

References (113)

1. Venkatachalam MA, Griffin KA, Lan R et al (2010) Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol 298(5):F1078–F1094
2. Ishani A, Xue JL, Himmelfarb J et al (2009) Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 20(1):223–228
3. Coca SG, Yusuf B, Shlipak MG et al (2009) Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 53(6):961–973
4. Campanholle G, Ligresti G, Gharib SA, Duffield JS (2013) Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am J Physiol Cell Physiol 304(7):C591–C603
5. Liu Y (2011) Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 7(12):684–696
6. Eyden B (2005) The myofibroblast: a study of normal, reactive and neoplastic tissues, with an emphasis on ultrastructure. Part 2—tumours and tumour-like lesions. J Submicrosc Cytol Pathol 37(3–4):231–296
7. Follonier Castella L, Gabbiani G, McCulloch CA, Hinz B (2010) Regulation of myofibroblast activities: calcium pulls some strings behind the scene. Exp Cell Res 316(15):2390–2401
8. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420–1428
9. Otranto M, Sarrazy V, Bonte F et al (2012) The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr 6(3):203–219
10. Friedman SL, Sheppard D, Duffield JS, Violette S (2013) Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 5(167):167
11. ∙ Grgic I, Campanholle G, Bijol V et al (2012) Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int 82(2):172–83. This work demonstrates that injury of tubular epithelial cells promotes fibrosis
12. Rastaldi MP, Ferrario F, Giardino L et al (2002) Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 62(1):137–146
13. Zeisberg M, Hanai J, Sugimoto H et al (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9(7):964–968
14. Iwano M, Plieth D, Danoff TM et al (2002) Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Investig 110(3):341–350
15. Phua YL, Martel N, Pennisi DJ et al (2013) Distinct sites of renal fibrosis in Crim1 mutant mice arise from multiple cellular origins. J Pathol 229(5):685–696
16. Kriz W, Kaissling B, Le Hir M (2011) Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest 121(2):468–474
17. ∙ Humphreys BD, Lin SL, Kobayashi A et al (2010) Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 176(1):85–97. These data reveal using genetic lineage tracing that FoxD1+ resident pericytes, perivascular fibroblasts, and interstitial fibroblasts give rise to myofibroblasts in renal fibrogenesis after unilateral ureteral obstruction
18. Roufosse C, Bou-Gharios G, Prodromidi E et al (2006) Bone marrow-derived cells do not contribute significantly to collagen I synthesis in a murine model of renal fibrosis. J Am Soc Nephrol 17(3):775–782
19. Lin SL, Kisseleva T, Brenner DA, Duffield JS (2008) Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173(6):1617–1627
20. ∙∙ Lebleu VS, Taduri G, O’Connell J et al (2013) Origin and function of myofibroblasts in kidney fibrosis. Nat Med 19(8):1047–53. This study employed a number of genetic models to dissect the relative contributions of bone marrow, resident kidney fibroblasts, kidney pericytes, endothelial cells, and epithelial cells. The authors concluded that resident fibroblasts account for the majority of myofibroblasts, with significant contributions from bone marrow and much smaller contributions from endothelial or epithelial cells. They did not observe a pericyte origin for myofibroblasts
21. Picard N, Baum O, Vogetseder A et al (2008) Origin of renal myofibroblasts in the model of unilateral ureter obstruction in the rat. Histochem Cell Biol 130(1):141–155
22. ∙∙ Goritz C, Dias DO, Tomilin N et al (2011) A pericyte origin of spinal cord scar tissue. Science 333(6039):238–42. These data reveal that pericytes are major players in scarring of the spinal cord after injury. The authors performed lineage tracing using Glast-CreER driver mice and demonstrated that Glast-expressing pericytes of the sppinal cord parenchyma expand, gain α-SMA, and become myofibroblasts after injury
23. Humphreys BD (2012) Targeting pericyte differentiation as a strategy to modulate kidney fibrosis in diabetic nephropathy. Semin Nephrol 32(5):463–470
24. Levinson RS, Batourina E, Choi C et al (2005) Foxd1-dependent signals control cellularity in the renal capsule, a structure required for normal renal development. Development 132(3):529–539
25. Hatini V, Huh SO, Herzlinger D et al (1996) Essential role of stromal mesenchyme in kidney morphogenesis revealed by targeted disruption of Winged Helix transcription factor BF-2. Genes Dev 10(12):1467–1478
26. Grgic I, Duffield JS, Humphreys BD (2012) The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 27(2):183–193
27. ∙∙ Dulauroy S, Di Carlo SE, Langa F et al (2012) Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med 18(8). This work demonstrates, using genetic fate mapping, that ADAM12+ and PDGFR-α+ pericytes are the major source of myofibroblasts in scarring of skeletal muscle and skin. Genetic ablation of ADAM12+ cells or knockdown of ADAM12 was able to ameliorate the severity of fibrosis
28. Chen YT, Chang FC, Wu CF et al (2011) Platelet-derived growth factor receptor signaling activates pericyte-myofibroblast transition in obstructive and post-ischemic kidney fibrosis. Kidney Int 80(11):1170–1181
29. Xiong J, Wang Y, Zhu Z et al (2007) NG2 proteoglycan increases mesangial cell proliferation and extracellular matrix production. Biochem Biophys Res Commun 361(4):960–967
30. Boor P, Floege J (2012) The renal (myo-)fibroblast: a heterogeneous group of cells. Nephrol Dial Transplant 27(8):3027–3036
31. Seikrit C, Henkel C, van Roeyen CR et al (2013) Biological responses to PDGF-AA versus PDGF-CC in renal fibroblasts. Nephrol Dial Transplant 28(4):889–900
32. Kida Y, Duffield JS (2011) Pivotal role of pericytes in kidney fibrosis. Clin Exp Pharmacol Physiol 38(7):467–473
33. Kida Y, Ieronimakis N, Schrimpf C et al (2013) EphrinB2 reverse signaling protects against capillary rarefaction and fibrosis after kidney injury. J Am Soc Nephrol 24(4):559–572
34. Basile DP (2004) Rarefaction of peritubular capillaries following ischemic acute renal failure: a potential factor predisposing to progressive nephropathy. Curr Opin Nephrol Hypertens 13(1):1–7
35. Eardley KS, Kubal C, Zehnder D et al (2008) The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 74(4):495–504
36. Seron D, Alexopoulos E, Raftery MJ et al (1990) Number of interstitial capillary cross-sections assessed by monoclonal antibodies: relation to interstitial damage. Nephrol Dial Transplant 5(10):889–893
37. Choi YJ, Chakraborty S, Nguyen V et al (2000) Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Hum Pathol 31(12):1491–1497
38. Schrimpf C, Xin C, Campanholle G et al (2012) Pericyte TIMP3 and ADAMTS1 modulate vascular stability after kidney injury. J Am Soc Nephrol 23(5):868–883
39. Lin SL, Chang FC, Schrimpf C et al (2011) Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol 178(2):911–923
40. Pohlers D, Beyer A, Koczan D et al (2007) Constitutive upregulation of the transforming growth factor-beta pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 9(3):R59
41. Huang C, Kim Y, Caramori ML et al (2002) Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system and diabetic nephropathy lesions in type 1 diabetes. Diabetes 51(12):3577–3581
42. Wygrecka M, Zakrzewicz D, Taborski B et al (2012) TGF-beta1 induces tissue factor expression in human lung fibroblasts in a PI3K/JNK/Akt-dependent and AP-1-dependent manner. Am J Respir Cell Mol Biol 47(5):614–627
43. Bujak M, Frangogiannis NG (2007) The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74(2):184–195
44. Munger JS, Sheppard D (2011) Cross talk among TGF-beta signaling pathways, integrins, and the extracellular matrix. Cold Spring Harb Perspect Biol 3(11):a005017
45. Li MO, Wan YY, Sanjabi S et al (2006) Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24:99–146
46. Roberts AB, Sporn MB, Assoian RK et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83(12):4167–4171
47. Sime PJ, Xing Z, Graham FL et al (1997) Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 100(4):768–776
48. Dennis PA, Rifkin DB (1991) Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA 88(2):580–584
49. Hyytiainen M, Penttinen C, Keski-Oja J (2004) Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci 41(3):233–264
50. Ramirez F, Sakai LY (2010) Biogenesis and function of fibrillin assemblies. Cell Tissue Res 339(1):71–82
51. Massague J (2012) TGFbeta signalling in context. Nat Rev Mol Cell Biol 13(10):616–630
52. Wrana JL, Attisano L, Wieser R et al (1994) Mechanism of activation of the TGF-beta receptor. Nature 370(6488):341–347
53. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113(6):685–700
54. Derynck R, Akhurst RJ (2007) Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol 9(9):1000–1004
55. Trachtman H, Fervenza FC, Gipson DS et al (2011) A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79(11):1236–1243
56. Chen HY, Huang XR, Wang W et al (2011) The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 60(2):590–601
57. Hawinkels LJ, Ten Dijke P (2011) Exploring anti-TGF-beta therapies in cancer and fibrosis. Growth Factors 29(4):140–152
58. Azuma A (2012) Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 6(2):107–114
59. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC (2003) TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 284(2):F243–F252
60. Lan HY (2011) Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci 7(7):1056–1067
61. Lan HY, Mu W, Tomita N et al (2003) Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 14(6):1535–1548
62. Santiago B, Gutierrez-Canas I, Dotor J et al (2005) Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Investig Dermatol 125(3):450–455
63. Akhurst RJ, Hata A (2012) Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 11(10):790–811
64. Clevers H, Nusse R (2012) Wnt/beta-catenin signaling and disease. Cell 149(6):1192–1205
65. Aberle H, Bauer A, Stappert J et al (1997) beta-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16(13):3797–3804
66. Mao J, Wang J, Liu B et al (2001) Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell 7(4):801–809
67. Li VS, Ng SS, Boersema PJ et al (2012) Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 149(6):1245–1256
68. Fathke C, Wilson L, Shah K et al (2006) Wnt signaling induces epithelial differentiation during cutaneous wound healing. BMC Cell Biol 7:4
69. Cheon SS, Cheah AY, Turley S et al (2002) beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA 99(10):6973–6978
70. Trensz F, Haroun S, Cloutier A et al (2010) A muscle resident cell population promotes fibrosis in hindlimb skeletal muscles of mdx mice through the Wnt canonical pathway. Am J Physiol Cell Physiol 299(5):C939–C947
71. Hsu E, Shi H, Jordan RM et al (2011) Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 63(3):783–794
72. Jones SE, Jomary C (2002) Secreted frizzled-related proteins: searching for relationships and patterns. BioEssays 24(9):811–820
73. Eguchi M, Nguyen C, Lee SC, Kahn M (2005) ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med Chem 1(5):467–472
74. Henderson WR Jr, Chi EY, Ye X et al (2010) Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA 107(32):14309–14314
75. Saraswati S, Alfaro MP, Thorne CA et al (2010) Pyrvinium, a potent small molecule Wnt inhibitor, promotes wound repair and post-MI cardiac remodeling. PLoS ONE 5(11):e15521
76. Surendran K, Simon TC, Liapis H, McGuire JK (2004) Matrilysin (MMP-7) expression in renal tubular damage: association with Wnt4. Kidney Int 65(6):2212–2222
77. He W, Dai C, Li Y et al (2009) Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 20(4):765–776
78. Dirocco DP, Kobayashi A, Taketo MM et al (2013) Wnt4/beta-catenin signaling in medullary kidney myofibroblasts. J Am Soc Nephrol [EPub ahead of print]
79. Hao S, He W, Li Y et al (2011) Targeted inhibition of beta-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol 22(9):1642–1653
80. Ren S, Johnson BG, Kida Y et al (2013) LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc Natl Acad Sci USA 110(4):1440–1445
81. von Toerne C, Schmidt C, Adams J et al (2009) Wnt pathway regulation in chronic renal allograft damage. Am J Transplant 9(10):2223–2239
82. van Roeyen CR, Ostendorf T, Floege J (2012) The platelet-derived growth factor system in renal disease: an emerging role of endogenous inhibitors. Eur J Cell Biol 91(6–7):542–551
83. Ostendorf T, Eitner F, Floege J (2012) The PDGF family in renal fibrosis. Pediatr Nephrol 27(7):1041–1050
84. Chuang PY, Menon MC, He JC (2013) Molecular targets for treatment of kidney fibrosis. J Mol Med (Berl) 91(5):549–559
85. Eitner F, Bucher E, van Roeyen C et al (2008) PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 19(2):281–289
86. Nusslein-Volhard C, Wieschaus E (1980) Mutations affecting segment number and polarity in Drosophila. Nature 287(5785):795–801
87. Briscoe J, Therond PP (2013) The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol 14(7):418–431
88. Yauch RL, Gould SE, Scales SJ et al (2008) A paracrine requirement for hedgehog signalling in cancer. Nature 455(7211):406–410
89. Choi SS, Omenetti A, Syn WK, Diehl AM (2011) The role of Hedgehog signaling in fibrogenic liver repair. Int J Biochem Cell Biol 43(2):238–244
90. Stewart GA, Hoyne GF, Ahmad SA et al (2003) Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. J Pathol 199(4):488–495
91. Mailleux AA, Moshai EF, Crestani B (2013) Sonic Hedgehog signaling in pulmonary fibrosis: a spiky issue? Am J Physiol Lung Cell Mol Physiol 304(6):L391–L393
92. Fabian SL, Penchev RR, St-Jacques B et al (2012) Hedgehog-Gli pathway activation during kidney fibrosis. Am J Pathol 180(4):1441–1453
93. Ding H, Zhou D, Hao S et al (2012) Sonic hedgehog signaling mediates epithelial–mesenchymal communication and promotes renal fibrosis. J Am Soc Nephrol 23(5):801–813
94. Sahebjam S, Siu LL, Razak AA (2012) The utility of hedgehog signaling pathway inhibition for cancer. Oncologist 17(8):1090–1099
95. Jenkins D (2009) Hedgehog signalling: emerging evidence for non-canonical pathways. Cell Signal 21(7):1023–1034
96. ∙ Kramann R, Floege J, Ketteler M et al (2012) Medical options to fight mortality in end-stage renal disease: a review of the literature. Nephrol Dial Transplant 27(12):4298–307. This review summarizes treatment strategies that have undergone randomized controlled clinical trials (RCTs) in ESRD patients with mortality reduction as a pre-specified study endpoint. Survival improvement in ESRD patients has been demonstrated only in telmisartan, candesartan, and carvedilol
97. Sarafidis PA, Khosla N, Bakris GL (2007) Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 49(1):12–26
98. Maschio G, Alberti D, Janin G et al (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334(15):939–945
99. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Lancet 349(9069):1857–1863
100. Ruggenenti P, Perna A, Benini R et al (1999) In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 10(5):997–1006
101. Remuzzi A, Gagliardini E, Sangalli F et al (2006) ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 69(7):1124–1130
102. Wu QQ, Wang Y, Senitko M et al (2011) Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1. Am J Physiol Renal Physiol 300(5):F1180–F1192
103. Pergola PE, Krauth M, Huff JW et al (2011) Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am J Nephrol 33(5):469–476
104. ∙∙ Pergola PE, Raskin P, Toto RD et al (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365(4):327–36. This study highlights the favorable results from a preliminary study of bardoxolone methyl on kidney function. It is important to note that, when bardoxolone methyl was tested in larger phase 3 trials, the positive effects of this trial vanished. An example of the necessity to understand a biological outcome in the context of a disease
105. Zoja C, Benigni A, Remuzzi G (2013) The Nrf2 pathway in the progression of renal disease. Nephrol Dial Transplant
106. Burnier M, Forni V (2012) Endothelin receptor antagonists: a place in the management of essential hypertension? Nephrol Dial Transplant 27(3):865–868
107. ∙ Mann JF, Green D, Jamerson K et al (2010) Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21(3):527–35. This study tested the endothelin receptor antagonis avosentan in patients with diabetic nephropathy. Previous studies have shown that blocking the endothelin pathway, particularly ETA receptors, could produce powerful anti-hypertensive effects that were beneficial in preclinical and clinical models of nephropathy. This clinical study used a dose of avosentan that was higher than previous studies indicated as safe, and resulted in trial discontinuation due to increased severe adverse effects and death in the experimental arms compared to the control arms. Deeper understanding of the biology of the endothelin pathway in the context of chronic kidney disease is warranted
108. Kohan DE, Pollock DM (2012) Endothelin antagonists for diabetic and non-diabetic chronic kidney disease. Br J Clin Pharmacol. doi:10.1111/bcp.12064
109. Davidson A (2010) Targeting BAFF in autoimmunity. Curr Opin Immunol 22(6):732–739
110. Vincent FB, Morand EF, Mackay F (2012) BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus. Immunol Cell Biol 90(3):293–303
111. Stohl W (2012) Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep 14(4):303–309
112. McCarthy DD, Kujawa J, Wilson C et al (2011) Mice overexpressing BAFF develop a commensal flora-dependent IgA-associated nephropathy. J Clin Investig 121(10):3991–4002
113. Xin G, Shi W, Xu LX et al (2012) Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol 26(4):683–690